Seres Therapeutics (MCRB) Enterprise Value: 2015-2025
Historic Enterprise Value for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $120.8 million.
- Seres Therapeutics' Enterprise Value rose 57.44% to $120.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.2 million, marking a year-over-year increase of 93.91%. This contributed to the annual value of $111.1 million for FY2024, which is 109.62% up from last year.
- Seres Therapeutics' Enterprise Value amounted to $120.8 million in Q3 2025, which was up 133.94% from $51.6 million recorded in Q2 2025.
- Over the past 5 years, Seres Therapeutics' Enterprise Value peaked at $1.8 billion during Q2 2021, and registered a low of $5.7 million during Q1 2024.
- Its 3-year average for Enterprise Value is $149.7 million, with a median of $76.7 million in 2024.
- Its Enterprise Value has fluctuated over the past 5 years, first crashed by 99.06% in 2024, then soared by 1,006.70% in 2025.
- Over the past 5 years, Seres Therapeutics' Enterprise Value (Quarterly) stood at $474.4 million in 2021, then rose by 8.85% to $516.4 million in 2022, then plummeted by 89.74% to $53.0 million in 2023, then surged by 109.62% to $111.1 million in 2024, then spiked by 57.44% to $120.8 million in 2025.
- Its Enterprise Value was $120.8 million in Q3 2025, compared to $51.6 million in Q2 2025 and $63.2 million in Q1 2025.